Risk of Ileus Added to Ozempic Label
Medically reviewed by Drugs.com.
By Physician’s Briefing Staff HealthDay Reporter
WEDNESDAY, Sept. 27, 2023 -- Ozempic will now be labeled as having the potential to block intestines. The U.S. Food and Drug Administration recently made the label update for the drug made by Novo Nordisk, without directly citing Ozempic as the cause for this condition.
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure," the label reads.
The side effect (ileus) is also listed on labels for the weight-loss drug Wegovy, also made by Novo Nordisk, and in the diabetes medication Mounjaro, made by Eli Lilly, CBS News reported.
Both Ozempic and Wegovy are known generically as semaglutide. Among more than 8,500 reports of gastrointestinal disorders after using semaglutide medications through June 30, ileus is mentioned in 33 cases, including two deaths, CBS News reported.
The two pharmaceutical companies that make these medications are both being sued for claims that the drugs can cause gastroparesis, or stomach paralysis, CBS News reported.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Ingestion Hazard Prompts Recall of Small Magnetic Balls
FRIDAY, Dec. 29, 2023 -- Citing thousands of hospitalizations and at least seven deaths linked to high-powered magnetic balls, the U.S. Consumer Product Safety Commission...
pH-Multichannel Intraluminal Impedance Monitoring Can ID GERD
FRIDAY, Dec. 29, 2023 -- For preschool-aged children, pH-multichannel intraluminal impedance (MII) monitoring is useful for diagnosing gastroesophageal reflux disease...
Retrograde Cricopharyngeus Dysfunction Often Not Discussed With PCPs
WEDNESDAY, Dec. 20, 2023 -- Patients with retrograde cricopharyngeus dysfunction (R-CPD), which refers to the cricopharyngeal muscle's inability to relax to allow the retrograde...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.